文献速递慢性肾脏病遗传性与小管间质肾病

B型利钠肽过表达改善多囊肾病大鼠模型肝肾纤维囊性病变

B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
PubMed 文献 · Kidney Int · 2017-04-14

该研究在多囊肾病(PKD)大鼠模型中评估鸟苷酸环化酶A激活对疾病进展的影响。持续产生B型利钠肽(BNP)显著降低肾脏重量、肾脏囊性指数和纤维化,并抑制肝囊肿生成;体外BNP抑制囊性上皮细胞增殖、降低纤维化基因表达并增加细胞内钙。提示靶向鸟苷酸环化酶A-cGMP轴可能为肝肾纤维囊性疾病提供新治疗策略。

要点

  • 持续BNP产生可减轻PKD大鼠肾脏重量、囊性指数和纤维化。
  • BNP在体内抑制肝囊肿生成,体外抑制囊性上皮细胞增殖。
  • 靶向鸟苷酸环化酶A-cGMP轴可能成为PKD新策略。

核心结论

  • 持续激活鸟苷酸环化酶A对多囊肾和肝病具有多方面改善作用,靶向该-cGMP轴可能为肝肾纤维囊性疾病提供新治疗策略。

研究设计与样本

  • 研究采用多囊肾病大鼠模型,评估持续B型利钠肽(BNP)产生对疾病进展的影响,并辅以体外细胞实验。

主要发现

  • 持续BNP产生显著降低肾脏重量、肾脏囊性指数和纤维化,并抑制肝囊肿生成。
  • 体外BNP降低囊性上皮细胞增殖、抑制纤维化基因表达并增加细胞内钙。

临床怎么用

  • 靶向鸟苷酸环化酶A-cGMP轴可能作为肝肾纤维囊性疾病的新型治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycystic kidney disease (PKD) involves progressive hepatorenal cyst expansion and fibrosis, frequently leading to end-stage renal disease. Increased vasopressin and cAMP signaling, dysregulated calcium homeostasis, and hypertension play major roles in PKD progression. The guanylyl cyclase A agonist, B-type natriuretic peptide (BNP), stimulates cGMP and shows anti-fibrotic, anti-hypertensive, and vasopressin-suppressive effects, potentially counteracting PKD pathogenesis. Here, we assessed the impacts of guanylyl cyclase A activation on PKD progression in a rat model of PKD. Sustained BNP production significantly reduced kidney weight, renal cystic indexes and fibrosis, in concert with suppressed hepatic cystogenesis in vivo. In vitro, BNP decreased cystic epithelial cell proliferation, suppressed fibrotic gene expression, and increased intracellular calcium. Together, our data demonstrate multifaceted effects of sustained activation of guanylyl cyclase A on polycystic kidney and liver disease. Thus, targeting the guanylyl cyclase A-cGMP axis may provide a novel therapeutic strategy for hepatorenal fibrocystic diseases.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Holditch SJ, Schreiber CA, Harris PC, et al. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease. Kidney Int. 2017. PMID: 28416225. doi:10.1016/j.kint.2017.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。